paradigm morning, with disease to treatment transform continued therapies two clinical cause genetically have have defined of towards to joining Good the in us and is root and the sickle quarter, FSHD. patients. potential dramatically today. progress everyone, we to for Stephanie. and thanks we bringing mission rare Thanks, treat At programs cell Fulcrum, the Currently, to our make this transformative diseases,
as process address populations. through moving regulatory and possible needs know significant exist are programs unmet patient both as to the these we that We to in development the committed rapidly
investments that and resulted continuing This mid-XXXX our to in IND we in our approximately also internal our cash and strategic runway prioritize to Esther proceeds announced in further, in to later a call. realignment to extended XXXX. for enables research mission. engine in has a us programs the time. offering that extended value-driving at on key our $XX In underwritten the SCD. update, financials invest details we clinical our next public and of of expect our are intended in execute FSHD our At runway X to We file position last on our we strong an August, treatment that are will closed net that million provide continue our into
with tolerable which lines as mechanism some and cell goal SCD induction of that has potential can such too to to clinical lacked initial in options. from independent therapy shown is including our our need HbF severity in oral emerging starting has sickle both the has reduce XX% disease, therapeutic with FTX-XXXX that HbF the effective cell support data VOCs, the Moving and editing that why cell gene which morbidity a been been sickle outcomes robust so are acute in evidence, unmet improve associated time, and a SCD. An Ib in broadly SCD Phase our treatment of FTX-XXXX trial increase data, for to disease baseline disease on that produce Ib frequency programs, the syndrome. increases has an Several is to both by goal the exciting. can disease sickle current genetics is addressed symptoms mortality anemia, human not is symptoms, X% pain, therapies. above including HbF and therapeutic far our chest fatigue program. debilitating and and reduce HbF-inducing agent a long for only address
disease FTX-XXXX that a potential patients rapidly compelling achieve for that We of it targeted able shown absolute have care. HbF future sickle is that of range within cell concept and clinicians increases HbF demonstrated the in standard have proof induces to protein
As effect of our as across with the work we and XXXX consistency and dose multiple monotherapy hydroxyurea. will focus cohorts response the the combination on understanding Phase and continues, continue on with XXXX, to Ib both in trial
In milligram enrollment our and the we into next X XX for ongoing XXXX. our have dose to milligrams dose milligram and addition continue selected to X cohort cohorts, as plan
enabling goal trial quality multiple cohorts our for a data is high across to to in have Our inform plans XXXX. registration
focused been have trial and clinical trial operations on conduct. We
During with with recruitment sickle we the our program have of increased the cell are and in of in the second have year, populations the areas disease. meaningful half efforts participating targeted of number sites living that people
use focused are that is cell extremely SCD SCD from of local the on community-based fight front we community disease. with feedback to connections sickle understand building the lines community been have therapy We of because new important. ease on that treat and organizations of the and we The been a the received accessibility partnerships clear. have The has
with small developing Our approach day providers. has of from molecule HbF and oral been can be response positive and induction once patients taken very met robust that deliver care a an health
in and program, on are registration the enabling currently is in moving intended Phase FSHD the where Now enrolling designed geographies. REACH a efficient trial. III we ex-U.S. U.S. highly our XX-week both to as was and REACH to trial be
quality can in progression at safety continued measured Halifax, open-label ongoing trial and showed their in open-label to of Scotia, Notably, the also a XX% the line bring disease the disease period of and need in losmapimod lose ReDUXX we during losmapimod to or patients. the that that mobility FSHD relentless and to slow extension. who XX-week well in devastating crossed Top of or stop demonstrated our a life. participants even trial XX-week trial an There disease II cases, by In to RWS, FSHD strength, to initial function, maintain for function workspace, the therapy period life and for is from generally and Phase in through safe was quality decline advances, trial a receive as People that decided is positioned shared Society common continue over that baseline. be who reachable first-to-market change progression, urgent in effect this with as Over tolerated. the maintenance ReDUXX. indicates Phase remain FSHD improve in our measures. muscular has of IIb independence World form the October, their maintain Data well arm with from Nova potential disease-modifying as its second seeing disease meeting dystrophy. some continued therapy results from the We result. to placebo in patients same those treatment of XX-week help initial initial Muscle a after most the XX-week demonstrated favorable losmapimod the profile slowed Losmapimod based to study on data extension from patients
interactions become FSHD. strong and program, patients the clinical our care continue in standard conviction of the We this community the have for losmapimod reinforce with to and for to potential
complete We XXXX. in expect enrollment trial Phase for III the to
Arroyo Johnson by drug served most neurologist Officer Pharmaceuticals training Johnson. development. As executive lead additions Arroyo Momenta we X to make our Chief Medical recently excited Chief Officer. the is continue acquisition & as welcome a He Dr. with to Medical team. through very as progress on our to Fulcrum of decades yesterday experience joined Santiago Dr. are programs, leadership by our X of X in we its
in have leadership in at experience clinical trials We incredibly the as towards and enabling confidence great to helm pleased registration our Dr. we XXXX. have are Arroyo's two look and of him organization having
in as was drug Bio Jacobs led, Chief than Dr. Jeff our multiple X. the Jacobs Scientific to programs appointed at We and from will and have Jacobs discovery concept stage Chief also recently has Officer more has Officer. of Dr. Dr. most December of years Fulcrum co-led studies. be as experience mentored joining Goldfinch and Scientific IND-enabling discovery XX
to board to quarter in next are the have filing I call third With Esther efforts our to towards our We results. to XXXX. IND thrilled review hand financial lead our both will that, over on
